A comparative study of disease genes and drug targets in the human protein interactome

BackgroundDisease genes cause or contribute genetically to the development of the most complex diseases. Drugs are the major approaches to treat the complex disease through interacting with their targets. Thus, drug targets are critical for treatment efficacy. However, the interrelationship between the disease genes and drug targets is not clear.ResultsIn this study, we comprehensively compared the network properties of disease genes and drug targets for five major disease categories (cancer, cardiovascular disease, immune system disease, metabolic disease, and nervous system disease). We first collected disease genes from genome-wide association studies (GWAS) for five disease categories and collected their corresponding drugs based on drugs' Anatomical Therapeutic Chemical (ATC) classification. Then, we obtained the drug targets for these five different disease categories. We found that, though the intersections between disease genes and drug targets were small, disease genes were significantly enriched in targets compared to their enrichment in human protein-coding genes. We further compared network properties of the proteins encoded by disease genes and drug targets in human protein-protein interaction networks (interactome). The results showed that the drug targets tended to have higher degree, higher betweenness, and lower clustering coefficient in cancer Furthermore, we observed a clear fraction increase of disease proteins or drug targets in the near neighborhood compared with the randomized genes.ConclusionsThe study presents the first comprehensive comparison of the disease genes and drug targets in the context of interactome. The results provide some foundational network characteristics for further designing computational strategies to predict novel drug targets and drug repurposing.

[1]  Robyn L. Ward,et al.  The role of BRCA mutation testing in determining breast cancer therapy , 2010, Nature Reviews Clinical Oncology.

[2]  C. Hoggart,et al.  Genome‐wide significance for dense SNP and resequencing data , 2008, Genetic epidemiology.

[3]  J. Kennedy,et al.  Genetics in schizophrenia: where are we and what next? , 2010, Dialogues in clinical neuroscience.

[4]  M. Daly,et al.  Genome-wide association studies for common diseases and complex traits , 2005, Nature Reviews Genetics.

[5]  Jianxin Wang,et al.  Prioritization of orphan disease-causing genes using topological feature and GO similarity between proteins in interaction networks , 2014, Science China Life Sciences.

[6]  David Warde-Farley,et al.  Dynamic modularity in protein interaction networks predicts breast cancer outcome , 2009, Nature Biotechnology.

[7]  Cheng Zhu,et al.  A vertex similarity-based framework to discover and rank orphan disease-related genes , 2012, BMC Systems Biology.

[8]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[9]  John P A Ioannidis,et al.  Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database , 2008, Nature Genetics.

[10]  Jeanette J McCarthy,et al.  Genomic Medicine: A Decade of Successes, Challenges, and Opportunities , 2013, Science Translational Medicine.

[11]  M. McCarthy,et al.  Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.

[12]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[13]  N. Campbell Genetic association database , 2004, Nature Reviews Genetics.

[14]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[15]  F. Collins,et al.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.

[16]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[17]  Paul Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft , 2007 .

[18]  Douglas F Easton,et al.  BRCA1 and BRCA2 mutations in a population-based study of male breast cancer , 2001, Breast Cancer Research.

[19]  Albert-László Barabási,et al.  Error and attack tolerance of complex networks , 2000, Nature.

[20]  D. Mathis,et al.  Immunometabolism: an emerging frontier , 2011, Nature Reviews Immunology.

[21]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[22]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[23]  G. Keating,et al.  Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. , 2010, Drugs.

[24]  Mishal N. Patel,et al.  Objective assessment of cancer genes for drug discovery , 2012, Nature Reviews Drug Discovery.

[25]  Zhongming Zhao,et al.  A comparative study of cancer proteins in the human protein-protein interaction network , 2010, BMC Genomics.

[26]  Jianmin Wu,et al.  PINA v2.0: mining interactome modules , 2011, Nucleic Acids Res..

[27]  L Carulli,et al.  Review article: diabetes, genetics and ethnicity , 2005, Alimentary pharmacology & therapeutics.

[28]  Russ B. Altman,et al.  PharmGKB: the Pharmacogenetics Knowledge Base , 2002, Nucleic Acids Res..

[29]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[30]  M. McCarthy,et al.  New methods for finding disease-susceptibility genes: impact and potential , 2003, Genome Biology.

[31]  Sun-Young Kong,et al.  Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer. , 2006, Cancer research and treatment : official journal of Korean Cancer Association.

[32]  S. Malpas Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. , 2010, Physiological Reviews.

[33]  Peggy Hall,et al.  The NHGRI GWAS Catalog, a curated resource of SNP-trait associations , 2013, Nucleic Acids Res..

[34]  R. Sharan,et al.  Protein networks in disease. , 2008, Genome research.

[35]  Marie-Pierre Dubé,et al.  Human monogenic disorders — a source of novel drug targets , 2006, Nature Reviews Genetics.

[36]  Yi Pan,et al.  Integration of breast cancer gene signatures based on graph centrality , 2011, BMC Systems Biology.

[37]  J. Nadeau,et al.  Finding Genes That Underlie Complex Traits , 2002, Science.

[38]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[39]  Jiang He,et al.  Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. , 2006, The American journal of medicine.

[40]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[41]  Taehan Am Hakhoe Cancer research and treatment : official journal of Korean Cancer Association. , 2001 .

[42]  Bing Zhang,et al.  WebGestalt: an integrated system for exploring gene sets in various biological contexts , 2005, Nucleic Acids Res..

[43]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[44]  Giske Ursin,et al.  Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. , 2006, Cancer research.

[45]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.